Clinical Scorecard: Model projects more childhood HBV infections with birth-dose policy changes

At a Glance

Key Highlights

• The model projected 255 chronic HBV infections with universal birth-dose vaccination, 303 with vaccination deferred until age 2 months, and 467 with shared clinical decision-making.
• Compared with universal birth-dose vaccination, projected chronic infections increased by 19% with deferred vaccination and 83% with shared clinical decision-making.
• At age 20 years, an estimated 232,000 children remained susceptible after universal birth-dose vaccination, compared with 474,000 after deferred vaccination and 1.8 million after shared clinical decision-making.
• With reduced uptake, projected chronic infections were 357 with deferred vaccination and 575 with shared clinical decision-making; projected susceptibility at age 20 was about 912,000 and 2.7 million, respectively.
• In a higher-risk scenario, projected chronic infections were 1,700 with deferred vaccination and 2,192 with shared clinical decision-making. Across 1,000 probabilistic sensitivity simulations, universal birth-dose vaccination resulted in fewer projected chronic infections than either alternative.
• The model did not simulate subsequent liver disease, mortality, onward transmission, or economic consequences.

Guideline-Based Recommendations

Diagnosis

Management

• The study modeled three vaccination strategies: universal vaccination at birth, universal vaccination beginning at age 2 months, and vaccination through shared clinical decision-making.

Monitoring & Follow-up

Risks

• Under the modeled base case, deferred vaccination and shared clinical decision-making were associated with more projected chronic childhood HBV infections and more children susceptible at age 20 than universal birth-dose vaccination.
• In a higher-risk scenario incorporating reduced birth-dose vaccination among infants born to mothers with positive or unknown hepatitis B surface antigen status, higher maternal HBV prevalence, and increased childhood exposure, projected chronic infections were 1,700 with deferred vaccination and 2,192 with shared clinical decision-making, compared with 255 under the base-case universal birth-dose strategy.
• The authors noted uncertainty in household and community transmission risks; the model did not account for partial immunity after an incomplete vaccine series or differences between household and community transmission.

Patient & Prescribing Data

Hypothetical cohort of 3.6 million US-born infants modeled through age 20 years.

The model assumed vaccine-series completion rates of 91% with universal birth-dose vaccination, 87% with deferred vaccination, and 50% with shared clinical decision-making. With uptake reduced to 75% and 26% for the latter two strategies, projected chronic infections were 357 and 575, and projected susceptibility at age 20 was about 912,000 and 2.7 million, respectively.

Clinical Best Practices

• Interpret the reported infection and susceptibility estimates as model projections, not observed clinical outcomes.
• The authors noted uncertainty in childhood exposure risks and that the model did not simulate liver disease, mortality, onward transmission, or economic outcomes.
• The authors noted that continued universal birth-dose recommendations from some state health departments and professional medical societies could limit the applicability of projections assuming broader implementation of federal changes.

Related Resources & Content

• Annals of Internal Medicine